| **Table S4. Infectious disease clinical trial attributes by study location: U.S., Non-U.S., and Both.** |
| --- |
|  | **Study Location** |
| **Parameter** | **U.S.-based** | **Non-U.S.-based** | **Both** |
| Primary purpose, N | 1026 | 1815 | 236 |
|  Treatment | 537 (52.3%) | 881 (48.5%) | 182 (77.1%) |
|  Prevention | 371 (36.2%) | 775 (42.7%) | 50 (21.2%) |
|  Other purpose | 118 (11.5%) | 159 (8.8%) | 4 (1.7%) |
| Intervention type, N | 1100 | 1896 | 241 |
|  Drug | 593 (53.9%) | 958 (50.5%) | 179 (74.3%) |
|  Procedure | 47 (4.3%) | 88 (4.6%) | 1 (0.4%) |
|  Biological/vaccine | 267 (24.3%) | 592 (31.2%) | 56 (23.2%) |
|  Behavioral | 125 (11.4%) | 68 (3.6%) | 5 (2.1%) |
|  Device | 34 (3.1%) | 56 (3.0%) | 2 (0.8%) |
|  Other intervention | 154 (14.0%) | 269 (14.2%) | 11 (4.6%) |
|  Vaccine | 256 (23.3%) | 577 (30.4%) | 45 (18.7%) |
| Lead sponsor, N | 1100 | 1896 | 241 |
|  Industry | 384 (34.9%) | 724 (38.2%) | 204 (84.6%) |
|  NIH | 160 (14.5%) | 25 (1.3%) | 16 (6.6%) |
|  U.S. federal | 46 (4.2%) | 20 (1.1%) | 3 (1.2%) |
|  Govt.-non-U.S. | 0 (0.0%) | 92 (4.9%) | 1 (0.4%) |
|  Acad./hosp. | 421 (38.3%) | 819 (43.2%) | 10 (4.1%) |
|  Consortium | 18 (1.6%) | 86 (4.5%) | 5 (2.1%) |
|  Other | 71 (6.5%) | 130 (6.9%) | 2 (0.8%) |
| Funding source, N | 1100 | 1896 | 241 |
|  Industry | 505 (45.9%) | 868 (45.8%) | 206 (85.5%) |
|  NIH | 254 (23.1%) | 55 (2.9%) | 26 (10.8%) |
|  Other | 341 (31.0%) | 973 (51.3%) | 9 (3.7%) |
| Trial facility, N | 1100 | 1896 | 241 |
|  Single facility | 687 (62.5%) | 1214 (64.0%) | 0 (0.0%) |
|  Multiple facilities | 413 (37.5%) | 682 (36.0%) | 241 (100.0%) |
| Enrollment, N | 1093 | 1869 | 241 |
| Median (IQR) | 75 (32, 260) | 150 (52, 408) | 210 (82, 520) |
| Sex/age, N | 1100 | 1896 | 241 |
|  Female | 76 (6.9%) | 120 (6.3%) | 12 (5.0%) |
|  Male | 39 (3.5%) | 63 (3.3%) | 2 (0.8%) |
|  Both | 985 (89.5%) | 1713 (90.3%) | 227 (94.2%) |
|  Restricted to childrena | 116 (10.5%) | 389 (20.5%) | 40 (16.6%) |
|  Excludes elderlyb | 521 (47.4%) | 938 (49.5%) | 96 (39.8%) |
| Masking/blinding | 1090 | 1880 | 240 |
|  Open | 577 (52.9%) | 1117 (59.4%) | 96 (40.0%) |
|  Single-blind | 101 (9.3%) | 180 (9.6%) | 13 (5.4%) |
|  Double-blind | 412 (37.8%) | 583 (31.0%) | 131 (54.6%) |
| Allocation, N | 1078 | 1860 | 238 |
|  Randomized | 761 (70.6%) | 1383 (74.4%) | 185 (77.7%) |
|  Nonrandomized | 317 (29.4%) | 477 (25.6%) | 53 (22.3%) |
| Number of arms, N | 1087 | 1856 | 238 |
|  One | 272 (25.0%) | 389 (21.0%) | 41 (17.2%) |
|  Two | 540 (49.7%) | 973 (52.4%) | 111 (46.6%) |
|  Three | 139 (12.8%) | 255 (13.7%) | 33 (13.9%) |
|  Four | 76 (7.0%) | 129 (7.0%) | 31 (13.0%) |
|  Five or more | 60 (5.5%) | 110 (5.9%) | 22 (9.2%) |
| Comparator, N | 985 | 1779 | 232 |
|  Active  | 386/985 (39.2%) | 867/1779 (48.7%) | 89/232 (38.4%) |
|  Placebo  | 261/985 (26.5%) | 383/1779 (21.5%) | 64/232 (27.6%) |
| Phase, N | 1100 | 1896 | 241 |
|  Phase 0 | 6 (0.5%) | 8 (0.4%) | 1 (0.4%) |
|  Phase 1 | 244 (22.2%) | 192 (10.1%) | 18 (7.5%) |
|  Phase 1/Phase 2 | 60 (5.5%) | 72 (3.8%) | 9 (3.7%) |
|  Phase 2 | 243 (22.1%) | 356 (18.8%) | 96 (39.8%) |
|  Phase 2/Phase 3 | 21 (1.9%) | 61 (3.2%) | 8 (3.3%) |
|  Phase 3 | 121 (11.0%) | 414 (21.8%) | 86 (35.7%) |
|  Phase 4 | 153 (13.9%) | 439 (23.2%) | 19 (7.9%) |
|  N/A | 252 (22.9%) | 354 (18.7%) | 4 (1.7%) |
| Overall status, N | 1100 | 1896 | 241 |
|  Not yet recruiting | 93 (8.5%) | 218 (11.5%) | 8 (3.3%) |
|  Recruiting | 463 (42.1%) | 741 (39.1%) | 84 (34.9%) |
|  Active, not recruiting | 173 (15.7%) | 266 (14.0%) | 65 (27.0%) |
|  Completed | 341 (31.0%) | 625 (33.0%) | 74 (30.7%) |
|  Terminated | 30 (2.7%) | 46 (2.4%) | 10 (4.1%) |
| DMC, N | 1100 | 1896 | 241 |
|  Has DMC | 360 (32.7%) | 725 (38.2%) | 94 (39.0%) |
|  No DMC | 558 (50.7%) | 780 (41.1%) | 71 (29.5%) |
|  DMC missing | 182 (16.5%) | 391 (20.6%) | 76 (31.5%) |
| Regional distributionc, N | 1100 | 1896 | 241 |
|  Africa | 0 (0.0%) | 260 (13.7%) | 37 (15.4%) |
|  Central America | 0 (0.0%) | 21 (1.1%) | 91 (37.8%) |
|  East Asia | 0 (0.0%) | 270 (14.2%) | 26 (10.8%) |
|  Europe | 0 (0.0%) | 827 (43.6%) | 113 (46.9%) |
|  Middle East | 0 (0.0%) | 72 (3.8%) | 21 (8.7%) |
|  North America | 1100 (100.0%) | 137 (7.2%) | 241 (100.0%) |
|  North Asia | 0 (0.0%) | 27 (1.4%) | 22 (9.1%) |
|  Pacifica | 0 (0.0%) | 64 (3.4%) | 44 (18.3%) |
|  South America | 0 (0.0%) | 137 (7.2%) | 52 (21.6%) |
|  South Asia | 0 (0.0%) | 104 (5.5%) | 20 (8.3%) |
|  Southeast Asia | 0 (0.0%) | 125 (6.6%) | 19 (7.9%) |
|  Unknown | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| The denominator for each variable is the number of trials reporting such data. “Other Purpose” includes “Diagnostic,” “Supportive Care,” “Screening,” “Health Services Research,” and “Basic Science.” For “Intervention Type,” the numerator is the number of trials with at least one intervention of this type. A study with multiple interventions may be represented in more than 1 intervention type; hence cumulative percentage will exceed 100%. “Other Intervention” includes “Radiation,” “Dietary Supplement,” and “Genetic.” The “Comparator” variable identifies the number of trials designating that particular comparator. Since a study may have both a placebo and an active comparator arm, the cumulative percentage may exceed 100%. The “Recruiting” variable under “Overall Status” includes trials recruiting by invitation. “Terminated” includes trials that have been terminated, suspended, or withdrawn. The numerator in the “Regional Distribution” variable is the number of trials with at least 1 study site in that respective region. A multisite study may be represented in more than 1 region; hence, the cumulative percentage will exceed 100%. Abbreviations: DMC, data monitoring committee; IQR, interquartile range; NIH, US National Institutes of Health. aChildren defined as ≤18 years of age. bElderly defined as >65 years of age. cIndividual countries by region are available at: http://www.clinicaltrials.gov/ct2/search/browse?brwse=locn\_cat. |